vs
莱迪思半导体（LSCC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
莱迪思半导体的季度营收约是再鼎医药的1.1倍（$145.8M vs $127.1M），再鼎医药同比增速更快（17.1% vs 9.3%），莱迪思半导体自由现金流更多（$44.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 8.4%）
莱迪思半导体是美国专注于低功耗现场可编程门阵列（FPGA）设计制造的半导体企业，1983年成立，1989年上市，总部位于俄勒冈州希尔斯伯勒硅林区，在圣何塞、上海、马尼拉、槟城、新加坡等地设有运营网点，截至2022年员工超1000人，年营收超6.6亿美元。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
LSCC vs ZLAB — 直观对比
营收规模更大
LSCC
是对方的1.1倍
$127.1M
营收增速更快
ZLAB
高出7.8%
9.3%
自由现金流更多
LSCC
多$70.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
8.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $145.8M | $127.1M |
| 净利润 | $-7.6M | — |
| 毛利率 | 68.5% | 51.0% |
| 营业利润率 | 30.7% | -54.6% |
| 净利率 | -5.2% | — |
| 营收同比 | 9.3% | 17.1% |
| 净利润同比 | 14.6% | — |
| 每股收益（稀释后） | $-0.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSCCZLAB
| Q1 26 | $145.8M | — | ||
| Q4 25 | — | $127.1M | ||
| Q3 25 | $133.3M | $115.4M | ||
| Q2 25 | $124.0M | $109.1M | ||
| Q1 25 | $120.2M | $105.7M | ||
| Q4 24 | $117.4M | $108.5M | ||
| Q3 24 | $127.1M | $101.8M | ||
| Q2 24 | $124.1M | $100.1M |
净利润LSCCZLAB
| Q1 26 | $-7.6M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $2.8M | $-36.0M | ||
| Q2 25 | $2.9M | $-40.7M | ||
| Q1 25 | $5.0M | $-48.4M | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $7.2M | $-41.7M | ||
| Q2 24 | $22.6M | $-80.3M |
毛利率LSCCZLAB
| Q1 26 | 68.5% | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | 67.9% | 59.5% | ||
| Q2 25 | 68.4% | 60.6% | ||
| Q1 25 | 68.0% | 63.6% | ||
| Q4 24 | 61.1% | 61.5% | ||
| Q3 24 | 69.0% | 64.1% | ||
| Q2 24 | 68.3% | 64.9% |
营业利润率LSCCZLAB
| Q1 26 | 0.7% | — | ||
| Q4 25 | — | -54.6% | ||
| Q3 25 | -1.2% | -42.3% | ||
| Q2 25 | 3.8% | -50.3% | ||
| Q1 25 | 5.8% | -53.3% | ||
| Q4 24 | -10.4% | -62.6% | ||
| Q3 24 | 5.9% | -66.6% | ||
| Q2 24 | 18.2% | -76.0% |
净利率LSCCZLAB
| Q1 26 | -5.2% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.1% | -31.2% | ||
| Q2 25 | 2.3% | -37.3% | ||
| Q1 25 | 4.2% | -45.8% | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 5.7% | -40.9% | ||
| Q2 24 | 18.2% | -80.2% |
每股收益（稀释后）LSCCZLAB
| Q1 26 | $-0.06 | — | ||
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $0.02 | $-0.03 | ||
| Q2 25 | $0.02 | $-0.04 | ||
| Q1 25 | $0.04 | $-0.04 | ||
| Q4 24 | $0.12 | $-0.09 | ||
| Q3 24 | $0.05 | $-0.04 | ||
| Q2 24 | $0.16 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $133.9M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $714.1M | $715.5M |
| 总资产 | — | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LSCCZLAB
| Q1 26 | $133.9M | — | ||
| Q4 25 | — | $689.6M | ||
| Q3 25 | $117.9M | $717.2M | ||
| Q2 25 | $107.2M | $732.2M | ||
| Q1 25 | $127.6M | $757.3M | ||
| Q4 24 | $136.3M | $779.7M | ||
| Q3 24 | $124.3M | $616.1M | ||
| Q2 24 | $109.2M | $630.0M |
股东权益LSCCZLAB
| Q1 26 | $714.1M | — | ||
| Q4 25 | — | $715.5M | ||
| Q3 25 | $706.4M | $759.9M | ||
| Q2 25 | $687.0M | $791.7M | ||
| Q1 25 | $707.9M | $810.8M | ||
| Q4 24 | $710.9M | $840.9M | ||
| Q3 24 | $703.5M | $667.7M | ||
| Q2 24 | $698.8M | $704.2M |
总资产LSCCZLAB
| Q1 26 | $883.1M | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | $844.4M | $1.2B | ||
| Q2 25 | $808.6M | $1.2B | ||
| Q1 25 | $823.6M | $1.2B | ||
| Q4 24 | $843.9M | $1.2B | ||
| Q3 24 | $853.7M | $985.3M | ||
| Q2 24 | $827.5M | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $57.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $44.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 30.2% | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $153.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流LSCCZLAB
| Q1 26 | $57.6M | — | ||
| Q4 25 | — | $-26.0M | ||
| Q3 25 | $47.1M | $-32.0M | ||
| Q2 25 | $38.5M | $-31.0M | ||
| Q1 25 | $31.9M | $-61.7M | ||
| Q4 24 | $45.4M | $-55.8M | ||
| Q3 24 | $44.0M | $-26.8M | ||
| Q2 24 | $21.9M | $-42.2M |
自由现金流LSCCZLAB
| Q1 26 | $44.0M | — | ||
| Q4 25 | — | $-26.7M | ||
| Q3 25 | $34.0M | $-35.0M | ||
| Q2 25 | $31.3M | $-33.9M | ||
| Q1 25 | $23.3M | $-63.2M | ||
| Q4 24 | $39.7M | $-58.4M | ||
| Q3 24 | $39.4M | $-28.2M | ||
| Q2 24 | $14.8M | $-42.9M |
自由现金流率LSCCZLAB
| Q1 26 | 30.2% | — | ||
| Q4 25 | — | -21.0% | ||
| Q3 25 | 25.5% | -30.4% | ||
| Q2 25 | 25.2% | -31.1% | ||
| Q1 25 | 19.4% | -59.9% | ||
| Q4 24 | 33.8% | -53.8% | ||
| Q3 24 | 31.0% | -27.7% | ||
| Q2 24 | 11.9% | -42.9% |
资本支出强度LSCCZLAB
| Q1 26 | 9.3% | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | 9.8% | 2.6% | ||
| Q2 25 | 5.8% | 2.6% | ||
| Q1 25 | 7.2% | 1.5% | ||
| Q4 24 | 4.9% | 2.4% | ||
| Q3 24 | 3.7% | 1.3% | ||
| Q2 24 | 5.8% | 0.7% |
现金转化率LSCCZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 16.86× | — | ||
| Q2 25 | 13.23× | — | ||
| Q1 25 | 6.35× | — | ||
| Q4 24 | 2.75× | — | ||
| Q3 24 | 6.12× | — | ||
| Q2 24 | 0.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSCC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
